Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 482

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 482
---
 on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796) contained
therein which became effective on July 18, 2024. The prospectus supplement was subsequently amended four times to increase the maximum
aggregate offering price under the ATM Agreement. From July 19, 2024 to August 1, 2024, the Company sold a total of 135,568 shares in
the ATM Offering for gross proceeds of $1,994,583.

On July 22, 2024 and July 26, 2024, the Company
converted 1,291 and 1,032 shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into 8,000 shares and 6,667
shares of common stock, respectively.

On October 1, 2024 and October 31, 2024, the
Company issued 41,311 shares and 45,800 shares of common stock, respectively upon the exercise of 41,311 and 45,800 September 2024 Pre-Funded
Warrants, respectively, resulting in aggregate cash proceeds to the Company of $436.

F-21

On December 10, 2024 and December 11, 2024, the
Company issued 50,800 shares and 56,600 shares of common stock, respectively, upon the exercise of 50,800 and 56,600 September
2024 Pre-Funded Warrants, respectively, resulting in aggregate cash proceeds to the Company of $537.

Common Stock Warrants

As of December 31, 2024, the Company accounts
for all issued and outstanding warrants to purchase common stock as equity-classified instruments based on the guidance in ASC 480 and
ASC 815.

In May 2022 and May 2023, in connection with
the issuance of the Related Party Notes and the 2022 and 2023 Bridge Notes as described in Note 7, the Company issued five-year warrants
to each of the noteholders with an exercise price dependent on the IPO price (collectively, the “Bridge Warrants”). The number
of shares issuable upon exercise of the warrants was contingent on the number of shares issued upon conversion of the notes following
the Company’s IPO. As of the closing of the Company’s IPO, the Bridge Warrants became exercisable into an aggregate of 3,870
shares of the Company’s common stock, 1